Involvement of adrenergic and serotonergic receptors in antidepressant-like effect of urocortin 3 in a modified forced swimming test in mice

Brain Research Bulletin

Volumn 77, Issue 5, 2008, Pages 301-305

  Tanaka, Masaru ^a   Telegdy, Gyula ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Depression; Receptors; Urocortins

Indexed keywords

ADRENERGIC RECEPTOR; CYPROHEPTADINE; METHYSERGIDE; PHENOXYBENZAMINE; PRAZOSIN; PROPRANOLOL; SEROTONIN RECEPTOR; UROCORTIN III; YOHIMBINE;

ANIMAL EXPERIMENT; ARTICLE; CLIMBING; CONTROLLED STUDY; DEPRESSION; DRUG ANTAGONISM; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANQUILIZING ACTIVITY;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; MALE; MICE; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; RECEPTORS, ADRENERGIC; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SWIMMING; UROCORTINS;

EID: 54549126030     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2008.08.012     Document Type: Article

References (33)

1. Balázsa T., Bíró J., Gullai N., Ledent C., and Sperlágh B. CB1-cannabinoid receptors are involved in the modulation of non-synaptic [3H]serotonin release from the rat hippocampus. Neurochem. Int. 52 1/2 (2008) 95-102
2. Bale T.L., Contarino A., Smith G.W., Chan R., Gold L.H., Sawchenko P.E., Koob G.F., Vale W.W., and Lee K.F. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat. Genet. 24 4 (2000) 410-414
3. Benkert O., Gründer G., and Wetzel H. Is there an advantage to venlafaxine in comparison with other antidepressants?. Hum. Psychopharmacol. 12 (1997) 53-64
4. Consoli D., Leggio G.M., Mazzola C., Micale V., and Drago F. Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?. Eur. J. Pharmacol. 573 1-3 (2007) 139-147
5. Detke M.J., Rickels M., and Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121 1 (1995) 66-72
6. Dhingra D., and Sharma A. Antidepressant-like activity of n-hexane extract of nutmeg (Myristica fragrans) seeds in mice. J. Med. Food 9 1 (2006) 84-89
7. Dhir A., and Kulkarni S.K. Effect of addition of yohimbine (alpha-2-receptor antagonist) to theantidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test. Pharmacology 80 4 (2007) 239-243
8. Dias Elpo Zomkowski A., Oscar Rosa A., Lin J., Santos A.R., Calixto J.B., and Lúcia Severo Rodrigues A. Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res. 1023 2 (2004) 253-263
9. Dunn A.J., and Berridge C.W. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?. Brain Res. Brain Res. Rev. 15 2 (1990) 71-100
10. Eriksson E. Antidepressant drugs: does it matter if they inhibit the reuptake of noradrenaline or serotonin?. Acta Psychiatr. Scand. Suppl. 402 (2000) 12-17
11. Evangelista S., Borsini F., and Meli A. Evidence that muscimol acts in the forced swimming test by activating the rat dopaminergic system. Life Sci. 41 24 (1987) 2679-2684
12. Gysling K., Forray M.I., Haeger P., Daza C., and Rojas R. Corticotropin-releasing hormone and urocortin: redundant or distinctive functions?. Brain Res. Brain Res. Rev. 47 1-3 (2004) 116-125
13. Hauger R.L., Grigoriadis D.E., Dallman M.F., Plotsky P.M., Vale W.W., and Dautzenberg F.M. International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol. Rev. 55 1 (2003) 21-26
14. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23 5 (2000) 477-501
15. Holsboer F. Prospects for antidepressant drug discovery. Biol. Psychol. 57 1-3 (2001) 47-65
16. Jahn O., Tezval H., van Werven L., Eckart K., and Spiess J. Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity. Neuropharmacology 47 2 (2004) 233-242
17. Khisti R.T., Chopde C.T., and Jain S.P. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol. Biochem. Behav. 67 1 (2000) 137-143
18. Kiss J.P. Theory of active antidepressants: a nonsynaptic approach to the treatment of depression. Neurochem. Int. 52 1/2 (2008) 34-39
19. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K., Donaldson C., Vaughan J., Reyes T.M., Gulyas J., Fischer W., Bilezikjian L., Rivier J., Sawchenko P.E., and Vale W.W. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98 13 (2001) 7570-7575
20. Linthorst A.C., Penalva R.G., Flachskamm C., Holsboer F., and Reul J.M. Forced swim stress activates rat hippocampal serotonergic neurotransmission involving a corticotropin-releasing hormone receptor-dependent mechanism. Eur. J. Neurosci. 16 12 (2002) 2441-2452
21. Mannucci C., Tedesco M., Bellomo M., Caputi A.P., and Calapai G. Long-term effects of nicotine on the forced swimming test in mice: an experimental model for the study of depression caused by smoke. Neurochem. Int. 49 5 (2006) 481-486
22. Muller M.B., and Wurst W. Getting closer to affective disorders: the role of CRH receptor systems. Trends Mol. Med. 10 8 (2004) 409-415
23. Murray C.J., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349 9064 (1997) 1498-1504 349
24. Pellergrino A.S., and Cushman A.J. Stereotaxic Atlas of the Rat Brain (1979), Plenum Press, New York pp. 8-57
25. Potter E., Behan D.P., Fischer W.H., Linton E.A., Lowry P.J., and Vale W.W. Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins. Nature 349 6308 (1991) 423-426
26. Regestein Q.R., Rose L.I., and Williams G.H. Psychopathology in Cushing's syndrome. Arch. Intern. Med. 130 1 (1972) 114-117
27. Reny-Palasse V., and Rips R. Potentiation by TRH of the effect of imipramine on the forced-swimming test. Br. J. Pharmacol. 85 2 (1985) 463-470
28. Reul J.M., and Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2 1 (2002) 23-33
29. Schechter L.E., Ring R.H., Beyer C.E., Hughes Z.A., Khawaja X., Malberg J.E., and Rosenzweig-Lipson S. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2 4 (2005) 590-611
30. Tanaka M., and Telegdy G. Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and Urocortin 3 in a modified forced swimming test in mice. Brain Res. Bull. 75 5 (2008) 509-512
31. Valdez G.R., Zorrilla E.P., Rivier J., Vale W.W., and Koob G.F. Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res. 980 2 (2003) 206-212
32. Vale W., Spiess J., Rivier C., and Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213 4514 (1981) 1394-1397
33. Venihaki M., Sakihara S., Subramanian S., Dikkes P., Weninger S.C., Liapakis G., Graf T., and Majzoub J.A. Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours. J. Neuroendocrinol. 16 5 (2004) 411-422